

PRODUCT INFORMATION




AZD 6244

Item No. 11599

CAS Registry No.: 606143-52-6
Formal Name: 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
Synonyms: ARRY-142886, CL 1,040, NSC 741078, Selumetinib

MF: C₁₇H₁₅BrClFN₄O₃
FW: 457.7
Purity: ≥95%
UV/Vis.: λ_{max}: 214, 258 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 6244 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 6244 in the solvent of choice. AZD 6244 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of AZD 6244 in these solvents is approximately 20 and 15 mg/ml, respectively.

AZD 6244 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZD 6244 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AZD 6244 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

MEK kinases are central components of diverse intracellular signaling pathways. MEK1 and MEK2 specifically act downstream of growth factor receptors and the proto-oncogenes Ras and Raf to activate ERK1 and ERK2, often leading to an increase in cell proliferation.¹ AZD 6244 is a potent, highly selective inhibitor of MEK1 and MEK2 (IC₅₀ = 14 and 530 nM, respectively).¹⁻³ It weakly inhibits the EGF receptor (IC₅₀ = 7.0 μM) and has no effect on a large panel of other kinases.² AZD 6244 suppresses the growth of tumors displaying high levels of phosphorylated MEK1/2 or ERK1/2.^{1,3} In addition to suppressing growth, it induces apoptosis and differentiation within tumors.⁴ AZD 6244 has potential, alone or in combination therapy, for promoting tumor regression in various forms of cancer, including those involving mutations of the proto-oncogenes Ras and Raf.^{5,6}

References

1. Yeh, T.C., Marsh, V., Bernat, B.A., *et al. Clin. Cancer Res.* **13**(5), 1576-1583 (2007).
2. Davis, M.I., Hunt, J.P., Herrgard, S., *et al. Nat. Biotechnol.* **29**(11), 1046-1051 (2011).
3. Huynh, H., Soo, K.C., Chow, P.K.H., *et al. Mol. Cancer Ther.* **6**(1), 138-146 (2007).
4. Davies, B.R., Logie, A., McKay, J.S., *et al. Mol. Cancer Ther.* **6**(8), 2209-2219 (2007).
5. Corcoran, R.B., Cheng, K.A., Hata, A.N., *et al. Cancer Cell* **23**(1), 121-128 (2013).
6. Robert, C., Dummer, R., Gutzmer, R., *et al. Lancet Oncol.* **14**(8), 733-740 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM